U.S. Markets close in 5 hrs 2 mins

Shire plc (SHP.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
3,755.00-116.00 (-3.00%)
As of 3:43PM BST. Market open.
People also watch
Full screen
Previous Close3,871.00
Bid3,755.00 x 71500
Ask3,756.50 x 58700
Day's Range3,745.00 - 3,842.50
52 Week Range3,745.00 - 3,933.00
Avg. Volume2,253,747
Market Cap33.85B
PE Ratio (TTM)N/A
Earnings DateOct 27, 2017
Dividend & Yield0.26 (0.54%)
Ex-Dividend Date2016-09-08
1y Target Est69.61
  • Reutersyesterday

    Denmark's ISS hit by headwind in Sweden and China, shares down

    Danish facility services company ISS A/S narrowed its 2017 growth forecast to the low end of its earlier range due to weak sales in Sweden and China, sending its shares down. * ISS has lost revenue in China 'on purpose' as it is leaving the low end of the retail marked, Chief Executive Jeff Gravenhorst told Reuters.

  • Shire Files Marketing Application for Lifitegrast in Europe
    Zacks2 days ago

    Shire Files Marketing Application for Lifitegrast in Europe

    Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.

  • American City Business Journals3 days ago

    Shire applies for European approval of potential blockbuster eye drop

    One of the state’s biggest biotech employers, Shire plc, has applied for European approval for its potential blockbuster eye drop to treat dry eye disease, sold by the name of Xiidra in the U.S. The drug, a twice-a-day eye drop that goes by the generic name of lifitegrast, was approved in the U.S. in August 2016. It’s touted as the “first and only” drug in the world to treat the signs and symptoms of dry eye disease, and competes head-to-head with Restasis, a similarly-priced drug sold by Allergan plc (AGN) that’s approved to increase tear production due to inflammation.